Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy.
PD-L1 expression
immune cells
malignant cells
molecular subtype
non-muscular invasive bladder cancer
relapse
survival
tumor grade
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 May 2020
21 May 2020
Historique:
received:
29
04
2020
revised:
15
05
2020
accepted:
19
05
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
28
5
2020
Statut:
epublish
Résumé
The goal of this study was to assess how PD-L1 expression in tissue specimens of patients with main molecular subtypes of NMIBC (luminal, basal and double-negative p53-mutant) associates with relapsed-free survival in dependence on the tumor grade and prior treatment of primary bladder cancer. PD-L1 expressions on the membrane of neoplastic and CD8+ immune cells were assessed in tumor specimens (
Identifiants
pubmed: 32455829
pii: cancers12051316
doi: 10.3390/cancers12051316
pmc: PMC7281187
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Russian academic excellence project "5-100" for Sechenov First Moscow State Medical University
ID : 5-100
Références
Eur Urol. 2017 Nov;72(5):801-813
pubmed: 28457661
Can Urol Assoc J. 2009 Dec;3(6 Suppl 4):S193-8
pubmed: 20019984
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Front Immunol. 2016 Nov 30;7:549
pubmed: 27965674
Drugs Today (Barc). 2017 Apr;53(4):217-237
pubmed: 28492290
J Urol. 2017 Oct;198(4):817-823
pubmed: 28487100
Eur J Surg Oncol. 2014 Jan;40(1):121-7
pubmed: 24140000
PLoS One. 2019 Aug 30;14(8):e0221785
pubmed: 31469885
Oncotarget. 2017 Aug 3;8(40):66849-66864
pubmed: 28978000
Cancer Immunol Immunother. 2018 Mar;67(3):403-412
pubmed: 29150702
Bladder Cancer. 2016 Jan 7;2(1):37-47
pubmed: 27376123
Cancer Immunol Immunother. 2007 Aug;56(8):1173-82
pubmed: 17186290
Hum Pathol. 2018 Nov;81:184-191
pubmed: 29969606
Cells. 2019 May 31;8(6):
pubmed: 31159302
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Curr Opin Oncol. 2015 May;27(3):185-90
pubmed: 25695463
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Oncol Lett. 2017 Jun;13(6):4818-4824
pubmed: 28599483
J Hematol Oncol. 2013 Sep 30;6(1):74
pubmed: 24283718
Cancer Immunol Immunother. 2007 May;56(5):739-45
pubmed: 17195077
BMC Urol. 2018 Nov 6;18(1):97
pubmed: 30400941
Lancet Oncol. 2016 Jul;17(7):e275
pubmed: 27321156
Nat Med. 1999 Dec;5(12):1365-9
pubmed: 10581077
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
EBioMedicine. 2016 Oct;12:105-117
pubmed: 27612592
Am J Surg Pathol. 2018 Aug;42(8):1059-1066
pubmed: 29750666
Clin Cancer Res. 2008 Aug 1;14(15):4800-8
pubmed: 18676751